胰高血糖素样肽-1类似物对实验性糖尿病大鼠的治疗作用  

Therapeutic effects of GLP-1 analog on rats with experimental diabetes mellitus

作　　者：赵海军[1] 徐琪[2] 张桂英[1] 刘娅[1] 于婷[1] 李鸿雁[1] 杨丽娜[1] 王洪莹[1] 谢丽波[1] 

机构地区：[1]吉林大学公共卫生学院营养与食品卫生教研室,吉林长春130021 [2]杭州中肽生化有限公司,浙江杭州310018

出　　处：《吉林大学学报（医学版）》2007年第3期474-479,共6页Journal of Jilin University：Medicine Edition

基　　金：吉林省科技发展重点资助课题(20050413-4);高等学校博士点基金资助课题(2005)

摘　　要：目的:探讨胰高血糖素样肽-1(GLP-1)类似物对实验性糖尿病的治疗作用。方法:84只Wistar大鼠随机分为正常对照组、高脂饲料组、GLP-1类似物低剂量组、GLP-1类似物中剂量组、GLP-1类似物高剂量组、糖尿病模型组和阳性对照组。采用高脂饲料饲养和注射40 mg.kg-1STZ方法建立实验性糖尿病动物模型。GLP-1类似物低、中、高剂量(1、10和100μg.kg-1)治疗7及14 d后,采用酶化学方法检测空腹血糖(FPG);治疗14 d后,采用酶化学方法检测血清总胆固醇(TC)、血清甘油三酯(TG)、低密度脂蛋白(LDL)、高密度脂蛋白(HDL);采用放射免疫方法检测血清胰岛素和C肽。结果:GLP-1类似物高剂量组(100μg.kg-1)大鼠较糖尿病模型组进食量明显降低(P<0.01),中剂量组(10μg.kg-1)、高剂量组(100μg.kg-1)大鼠较糖尿病模型组饮水量均明显减少(P<0.01),各治疗组大鼠体重与糖尿病模型组比较差异均无显著性(P>0.05);GLP-1类似物高剂量组(100μg.kg-1)、中剂量组(10μg.kg-1)大鼠空腹血糖(FPG)较糖尿病模型组均明显降低(P<0.01);GLP-1类似物高剂量组(100μg.kg-1)大鼠血清TG较糖尿病模型组显著性降低(P<0.01);GLP-1类似物中剂量组(10μg.kg-1)、GLP-1类似物高剂量组(100μg.kg-1)LDL较糖尿病模型组均明显降低(P<0.01);GLP-1类似物中剂量组(10μg.kg-1)、高剂量组(100μg.kg-1)血清胰岛素和C肽水平较糖尿病模型组均显著升高(P<0.05)。结论:GLP-1类似物可以通过多种途径在治疗实验性糖尿病中发挥作用。Objective To investigate the therapeutic effects of glucagon-like peptide-1 （GLP-1） analog on rats with experimental diabetes mellitus. Methods Eighty-four Wistar rats were divided randomly into normal control group, high fat forage group, low-dose GLP-1 analog group, middle-dose GLP-1 analog group, high-dose GLP-1 analog group, diabetes mellitus model group and positive control group. Diabetes mellitus animal models were induced with high fat forage and injection of 40 mg · kg^-1 STZ. After 7 and 14 d of GLP-1 analog therapy, the level of fasting plasma glucose （FPG） was detected with enzyme-chemical method. After 14 d of GLP-1 analog therapy, the levels of serum total cholesterols （TC）, triglyceride （TG）, low-denslty lipoprotein （LDL） and highdensity lipoprotein （HDL） were detected with enzyme-chemical method. The levels of serum insulin and C-peptide were measured with immunoradiometric assay method. Results After 14 d of GLP-1 analog injection, food intake in high-dose GLP-1 analog （100 μg · kg^-1） group was less than that in DM group （P〈0.01）; Water intake in middle-dose GLP-1 analog （10 μg · kg^-1） group and high dose （100 μg · kg^-1） group were less than that in DM group （P〈0.01）. There were no statistical differences of body weight between all therapeutic groups and DM group （P〈0.05）. The levels of FPG in middle-dose GLP-1 analog （10 μg · kg^-1） group and high dose （100μg · kg^-1） group were lower than that in DM group （P〈0.01）. The level of TG in high-dose GLP-1 analog （100 μg · kg^-1） group was lower than that in DM group （P〈0.01）. The levels of LDL in middle-dose GLP-1 analog （10μg · kg^-1） group and high dose （100 μg · kg^-1） group were lower than that in DM group （P〈0. 01）. The levels of serum insulin and C-peptide in middle-dose GLP-1 analog （10μg · kg^-1） group and high dose （100 μg · kg^-1） group were higher than that in DM group （P〈0. 05） . Conclusion GLP-1 analog can pal

关 键 词：胰高血糖素样肽-1 糖尿病 实验性 胰岛素 C肽 

分 类 号：R587.1[医药卫生—内分泌] R-332[医药卫生—内科学]